Amgen's (AMGN -0.3%) melanoma drug meets its primary endpoint in a Phase 3 clinical trial but misses its secondary.
The study evaluated the safety and efficacy of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor ((GM-CSF)).
The primary endpoint of durable response rate was met but the secondary endpoint of overall survival was not.
EVP of R&D Sean Harper, M.D. says the company will conduct further research on the product's efficacy in melanoma.